The introduction and broad use of new immunosuppressive agents, including biologic
agents and JAK inhibitors, have revolutionised treatment of inflammatory bowel disease …

2. Methods This document represents the third version of the European Consensus on
reproduction in IBD. The development of this Consensus included the formulation of …

• Increasingly, pregnant patients with inflammatory or autoimmune diseases use monoclonal
antibody biologics before conception, during pregnancy and while breastfeeding.• A minority …

Despite the fact that knowledge on obstetrical management of Inflammatory Bowel Diseases
(IBDs) has greatly improved over the years, many patients still actively avoid pregnancy for …

Background & Aims Little is known about in utero exposure to and postnatal clearance of
anti–tumor necrosis factor (anti-TNF) agents in neonates. We investigated the …

Background: Patients with immune-mediated diseases on immunosuppressive therapies
have more infectious episodes than healthy individuals, yet vaccination practices by …

Abstract Background and Aims For women with inflammatory bowel disease [IBD], it is not
very well known how IBD or IBD treatment affects their breast milk components. We aimed to …

Exposure in utero and elimination of Adalimumab and Infliximab in neonates (the ERA study): a
prospective cohort study Page 1 1 Tofacitinib concentrations in plasma and breast milk of a …

Objective To review currently available data on the transfer of monoclonal antibodies (mAbs)
in the breastmilk of women receiving treatment for neurologic and non-neurologic diseases …

Inflammatory bowel diseases, namely ulcerative colitis and Crohn's disease, occur
worldwide and affect people of all ages, with a high impact on their quality of life. Sex …